COVID-19 Collection

Journal article

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Abstract:: Background
A previous efficacy trial found benefit from inhaled budesonide for COVID-19 in patients not admitted to hospital, but effectiveness in high-risk individuals is unknown. We aimed to establish whether inhaled budesonide reduces time to recovery and COVID-19-related hospital admissions or deaths among people at high risk of complications in the community.
Methods
PRINCIPLE is a multicentre, open-label, multi-arm, randomised, cont... Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Yu, L.-M., Bafadhel, M., Dorward, J. J., Hayward, G., Saville, B. R., Gbinigie, O., Van Hecke, O., Ogburn, E., Evans, P. H., Thomas, N. P. B., Patel, M. G., Richards, D., Berry, N., Detry, M. A., Saunders, C., Fitzgerald, M., Harris, V., Shanyinde, M., de Lusignan, S., … Ramakrishnan, S. (2021). Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. The Lancet, 398(10303), P843–855.

MLA Style

Yu, L-M, et al. “Inhaled Budesonide for COVID-19 in People at High Risk of Complications in the Community in the UK (PRINCIPLE): a Randomised, Controlled, Open-Label, Adaptive Platform Trial.” The Lancet, vol. 398, no. 10303, 2021, pp. P843–855.

Chicago Style

Yu, L-M, M Bafadhel, JJ Dorward, et al. 2021. “Inhaled Budesonide for COVID-19 in People at High Risk of Complications in the Community in the UK (PRINCIPLE): a Randomised, Controlled, Open-Label, Adaptive Platform Trial.” The Lancet 398 (10303): P843–855.
Print

Access Document

Files:: Yu_et_al_2021_Inhaled_budesonide_for.pdf

(Preview, Version of record, pdf, 814.5KB, Terms of use)

Publisher copy:: 10.1016/s0140-6736(21)01744-x

Authors

+ Yu, L-M More by this author

Role:: Author

+ Bafadhel, M More by this author

Role:: Author

+ Dorward, JJ More by this author

Institution:: University of Oxford
Role:: Author

+ Hayward, G More by this author

Role:: Author

+ Saville, BR More by this author

Role:: Author

More authors...

Publisher:: Elsevier
Journal:: The Lancet More from this journal
Volume:: 398
Issue:: 10303
Pages:: P843-855
Publication date:: 2021-08-10
Acceptance date:: 2021-07-20
DOI:: 10.1016/s0140-6736(21)01744-x
ISSN:: 0140-6736

Language:: English
Keywords:: FFR
Pubs id:: 1190406
Local pid:: pubs:1190406
Deposit date:: 2021-08-11
ARK identifier:: ark:/29072/ora_2819ecbe1b2e4c2ab1119a1d92b6c908

Terms of use

Copyright holder:: Yu et al.
Copyright date:: 2021
Rights statement:: ©2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license

Licence:: CC Attribution (CC BY)

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP